Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple Self-Swab revolutionize cervical cancer screening?

NCT ID NCT07768787

Diagnosis Sponsor: AML Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This trial tests whether a vaginal self-sampling device can accurately detect high-risk human papillomavirus (HPV) compared to samples collected by a clinician. About 1,000 women aged 30-64, either regular screening attendees or those who haven't been screened in 3+ years, will provide both self-collected and clinician-collected samples. The goal is to see if self-sampling could be a reliable option to increase participation in cervical cancer screening programs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Abbott Multi-Collect Specimen Collection Swab (a vaginal self-sampling device)
What this could lead to
If self-sampling proves accurate, it could make cervical cancer screening easier and more accessible, potentially increasing participation and early detection.
What could go wrong
The trial is a validation study, so it may show that self-collected samples are less accurate than clinician-collected ones. Also, results may not apply to all populations or screening settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,000 people

The number who actually took part.

Started

Sep 2024

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women attending a participating gynecology practice were recruited for this study. The population included women from a routine cervical cancer screening setting and women who had not recently participated in cervical cancer screening.

Ages

30 to 64 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 30-64 years. * Women that regularly attend screening with negative HR-HPV-result on the RIATOL assay at previous screen within the past 3 years OR women that did not attend screening during the past 3 years or longer. Exclusion Criteria: * Women treated for cervical cancer (hysterectomized). * Pregnant women. * Menstruating women * Non-consenting women. * Women unable to understand and/or sign informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical carcinoma human papilloma virus infection Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical carcinoma Human papilloma virus Human papilloma virus related cervical carcinoma

Contacts and locations

Locations

  • O+ Medicale

    Brussels, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.